Nasdaq · Healthcare
Aurinia Pharmaceuticals Inc. (AUPH)
As-reported financials and recent SEC filings for Aurinia Pharmaceuticals Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$283.1M
Net income
$287.2M
Net margin
101.5%
Diluted EPS
$2.07
ROE
49.4%
P/E (TTM)
8.0×
Market cap
$2.22B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M |
| Gross profit | $250.4M | $206.9M | $161.4M | — | — |
| Operating income | $104.9M | $-4.7M | $-91.7M | $-111.5M | $-180.7M |
| Net income | $287.2M | $5.8M | $-78.0M | $-108.2M | $-181.0M |
| Diluted EPS | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →1442026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →8-K2026-06-04
View on EDGAR →SCHEDULE 13D/A2026-06-04
View on EDGAR →Go deeper on AUPH
Search Aurinia Pharmaceuticals Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.